Starter en tråd om Saniona AB (SANION.ST) siden en del har den i favoritt-listen eller i porteføljen sin
Saniona AB (publ), a research and development company, engages in the discovery and development of drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain in Denmark. It has a portfolio of various drug candidates in pre-clinical and clinical stages.
The company’s products include AN788, a clinical candidate for second line treatment of major depressive disorder; AN761, a nicotinic a7 agonist to treat cognition deficits in schizophrenia and Alzheimer’s; and Tesofensine, a triple monoamine reuptake inhibitor, which is in Phase I and Phase II human clinical studies to treat obesity and type 2 diabetes. Its product pipeline also includes Tesomet, a fix-dosed combination of tesofensine and metoprolol for the treatment of type 2 diabetes and Prader-Willi syndrome; NS2359, a triple monoamine reuptake inhibitor to treat cocaine addiction; and AN363, a GABAA a2/a3 program for treatment of neuropathic pain.
In addition, the company is developing AN346 to treat inflammatory bowel diseases; and nicotinic a6 program for the treatment of Parkinson’s diseases. The company has drug discovery and development collaborations with Boehringer Ingelheim GmbH to develop small molecule therapeutics for the treatment of schizophrenia; Luc Therapeutics Inc.
for the treatment of ataxia; and Upsher-Smith Laboratories to treat neurological disorders, as well as Proximagen Ltd. and Productos Medix, S.
A de S.V.
Saniona AB (publ) was founded in 2011 and is headquartered in Ballerup, Denmark.
La oss starte diskusjonen! @paracelsus @Frank3000 @pdx